Pols H A P, Wittenberg J
Erasmus Medisch Centrum Rotterdam, locatie Dijkzigt, afd. Inwendige Geneeskunde, Rotterdam.
Ned Tijdschr Geneeskd. 2002 Jul 20;146(29):1359-63.
Risk factors for osteoporotic fractures that can be used for case-finding according to the recent guidelines from the Dutch Institute for Health Care Improvement (CBO) include: a vertebral fracture, a fracture past the age of 50, a positive family history, low body weight, severe immobility and the use of corticosteroids. Measurement of bone mineral density (BMD) is only recommended for case-finding and not for population screening. Measurement of the BMD is advised in women > or = 50 years of age with a fracture, women with a vertebral fracture regardless of age, women > or = 60 years of age with three of the following risk factors, and women > or = 70 years of age with two of the following risk factors: positive family history, low body weight and severe immobility. Persons with less than 1000-1200 mg calcium in their daily food who are using corticosteroids, persons with osteoporotic fractures and persons who are being treated with drugs for osteoporosis are eligible for calcium supplementation. Vitamin D supplementation is recommended for persons who do not come outdoors. For the drug treatment of osteoporosis in the first years after menopause, oestrogens, tibolone and raloxifene may be used. It is recommended that postmenopausal women with one or more osteoporotic vertebral fractures or an increased risk and a T-score below -2.5 be treated with a bisphosphonate. Patients who are expected to be treated with > or = 15 mg prednisolone equivalent per day for more than 3 months and postmenopausal women and older men (> or = 70) who will be treated with > or = 7.5 mg prednisolone equivalent per day should be started on a bisphosphonate as soon as possible. Other patients who will be treated with > or = 7.5 mg prednisolone equivalent per day should take a bisphosphonate if their Z-score is below -1 or their T-score is below -2.5.
根据荷兰医疗保健改善研究所(CBO)最近的指南,可用于病例筛查的骨质疏松性骨折风险因素包括:椎体骨折、50岁之后发生的骨折、家族史阳性、体重过低、严重活动受限以及使用皮质类固醇。仅建议测量骨密度(BMD)用于病例筛查,而非人群筛查。建议对以下人群测量骨密度:50岁及以上发生骨折的女性、无论年龄有椎体骨折的女性、60岁及以上有以下三种风险因素中的三种的女性,以及70岁及以上有以下两种风险因素中的两种的女性:家族史阳性、体重过低和严重活动受限。每日食物中钙摄入量低于1000 - 1200毫克且正在使用皮质类固醇的人、骨质疏松性骨折患者以及正在接受骨质疏松药物治疗的人适合补充钙。建议不出户外的人补充维生素D。绝经后最初几年骨质疏松的药物治疗可使用雌激素、替勃龙和雷洛昔芬。建议有一处或多处骨质疏松性椎体骨折或风险增加且T值低于 - 2.5的绝经后女性使用双膦酸盐治疗。预计每天接受相当于15毫克泼尼松龙治疗超过3个月的患者以及将接受相当于每天7.5毫克泼尼松龙治疗的绝经后女性和老年男性(70岁及以上)应尽快开始使用双膦酸盐。其他预计每天接受相当于7.5毫克泼尼松龙治疗的患者,如果其Z值低于 - 1或T值低于 - 2.5,应服用双膦酸盐。